

Research article

## A *necdin*/*MAGE*-like gene in the chromosome 15 autism susceptibility region: expression, imprinting, and mapping of the human and mouse orthologues

Thea K Chibuk, Jocelyn M Bischof and Rachel Wevrick\*

Address: Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada

E-mail: Thea K Chibuk - [tchibuk@gpu.srv.ualberta.ca](mailto:tchibuk@gpu.srv.ualberta.ca); Jocelyn M Bischof - [jbischof@ualberta.ca](mailto:jbischof@ualberta.ca); Rachel Wevrick\* - [rachel.wevrick@ualberta.ca](mailto:rachel.wevrick@ualberta.ca)

\*Corresponding author

Published: 20 December 2001

Received: 1 October 2001

*BMC Genetics* 2001, **2**:22

Accepted: 20 December 2001

This article is available from: <http://www.biomedcentral.com/1471-2156/2/22>

© 2001 Chibuk et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [info@biomedcentral.com](mailto:info@biomedcentral.com)

### Abstract

**Background:** Proximal chromosome 15q is implicated in neurodevelopmental disorders including Prader-Willi and Angelman syndromes, autistic disorder and developmental abnormalities resulting from chromosomal deletions or duplications. A subset of genes in this region are subject to genomic imprinting, the expression of the gene from only one parental allele.


**Results:** We have now identified the *NDNL2* (also known as *MAGE-G*) gene within the 15q autistic disorder susceptibility region and have mapped its murine homolog to the region of conserved synteny near *necdin* (*Ndn*) on mouse Chr 7. *NDNL2/MAGE-G* is a member of a large gene family that includes the X-linked *MAGE* cluster, *MAGED1* (*NRAGE*), *MAGEL2* and *NDN*, where the latter two genes are implicated in Prader-Willi syndrome. We have now determined that *NDNL2/Ndnl2* is widely expressed in mouse and human fetal and adult tissues, and that it is apparently not subject to genomic imprinting by the PWS/AS Imprinting Center.

**Conclusion:** Although *NDNL2/MAGE-G* in the broadly defined chromosome 15 autistic disorder susceptibility region, it is not likely to be pathogenic based on its wide expression pattern and lack of imprinted expression.

### Background

Human chromosome 15q is prone to cytogenetic rearrangements, in part due to repetitive elements located therein [1,2]. Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two neurodevelopmental disorders caused by deletions of 15q11-q13, and neurodevelopmental abnormalities are associated with supernumerary chromosomes derived from inverted duplications of 15q [3]. In addition, an autistic disorder susceptibility locus has been localized to proximal 15q by linkage and association studies [4,5]. AS is associated

with *UBE3A* mutations [6,7]. Strong candidates for PWS have recently emerged and are likely to have an additive effect in causing this disorder [8–12]. In particular, two members of the *NDN/MAGE* gene family, *NDN* and *MAGEL2*, are located in the PWS deletion region and are inactivated in individuals with PWS [8,11–14]. Respiratory and behavioral abnormalities in a mouse deleted for *Ndn*, the murine orthologue of *NDN*, may suggest that *NDN* is implicated in the PWS phenotype [15,16]. We have therefore investigated the possibility that other *NDN/MAGE* genes may also be present on proximal 15q



**Figure 1**  
**Map of the human 15q11-q14 region.** Location of *NDNL2* was derived from the Ensembl Human Genome server [http://www.ensembl.org/] and the physical location of *APBA2*, which is located on the same genomic clone as *NDNL2*. The large double-headed arrow indicates the common PWS/AS deletion, and BP2 and BP3 indicate the most common proximal and distal breakpoint regions. The breakpoint region for the largest inv dup (15) chromosome [27] and the autistic disorder susceptibility region [5] are also indicated. The physical distance between BP3 and *APBA2/NDNL2* is as yet unknown due to the presence of repetitive elements in the intervening region.

and may be involved in neurodevelopmental disorders. Indeed, we identified a novel neclin-related gene, *NDNL2*, on proximal 15q within the critical region for autistic disorder susceptibility. We have examined the expression of *NDNL2* and its murine orthologue, and placed the murine gene on Chr. 7. The proximal region of chromosome 15 is subject to genomic imprinting, the expression of a gene from only one allele depending on parent-of-origin. Furthermore, the maternal derivation of chromosome 15 abnormalities seen in individuals with autistic disorder suggests a parent-of origin effect [4,5]. We have therefore analyzed the imprinting of human and mouse *NDNL2/NdnL2*.

## Results and discussion

Using a BLAST search for genes with sequence similarity to *NDN*, *NDNL2* was identified as a MAGE-like protein on the BAC clone RP11-18H24 (GenBank accession AC016484). This clone also contains the *APBA2* gene which has been physically mapped to within the critical

region for a 15q autistic disorder susceptibility locus, and outside the PWS/AS deletion region [4,5] (Fig. 1). An open reading frame of 472 amino acids was predicted from the genomic sequence of *NDNL2* and is located within a single exon of the predicted gene. A series of expressed sequence tags (ESTs) were identified through a BLAST search of the EST database and were found to be part of the Unigene cluster Hs.94011. Assembly of the ESTs into a consensus sequence was performed and this sequence was compared to our sequence of IMAGE clones representing *NDNL2* to arrive at a final sequence for the predicted protein (Fig. 2) (also see partial sequence in GenBank AF320911, MAGE-G).

The sequence for murine *NdnL2* was identified using sequence data obtained from homology searches of mouse ESTs (UniGene cluster Mm.19944). Comparison of the sequence from multiple cDNAs revealed that the predicted mouse protein has 279 amino acids and has 83% sequence identity with the human protein (Fig. 2). As with other *NDN/MAGE* family members, the maximum sequence conservation is in the C-terminus of the protein, suggesting a common function for this domain among family members. The murine protein is truncated at the N terminus compared to the human protein at the position equivalent to the methionine at position 168 in the human predicted protein, predicted based on the presence of a strong Kozak consensus surrounding the murine AUG, including a G at the minus three position. In at least two EST clones, including RIKEN clone AKO10294 from a library enriched for full-length cDNAs, the predicted amino acids upstream of the putative murine start methionine are not conserved with the human sequence, in sharp contrast with those C-terminal to this methionine (Fig. 2). In addition, the lack of conservation does not appear to be due to the presence of an intron or a sequencing error. Closer inspection of the sequence revealed that *NDNL2* contains only partial similarity to the antigenic nonapeptide characteristic of other MAGE family proteins (Fig. 2). *NdnL2* is identical in sequence to a predicted protein named "mage-g1" (GenBank accession AF319979).

We identified a DNA polymorphism within *NdnL2* by direct sequencing of a 469 bp PCR product amplified from *M. musculus* strain C57BL/6JEi and *M. spretus* SPRET/Ei DNA. The presence of a T to C transition at position 42 of AV005659 abolishes an *Msp* I site in C57BL/6JEi that is present in SPRET/Ei. By genotyping the Jackson laboratory BSS backcross derived from the cross (C57BL/6JEi × SPRET/Ei)F1 × SPRET/Ei, we demonstrated linkage of *NdnL2* to chromosome 7, at a position genetically inseparable from that of *Ndn* (see Mouse Genome Informatics, [http://www.informatics.jax.org/] for details). As predicted from the location of human *APBA2*




**Figure 2**  
**Sequence comparison of human NDNL2 and mouse Ndn12 sequence.** The human and mouse predicted amino acid sequences are aligned with conserved amino acids shaded. Partial sequence of two cDNA clones has been included for comparison of the predicted translation with the longer human open reading frame. The predicted position of a MAGE-like nonpeptide present in other MAGE proteins is underlined.

near *NDNL2*, the murine *Apba2* gene is also located in the central region of Chr 7, but the use of different mapping panels for the two genes does not permit their relative order to be established [17]. Based on the high sequence similarity between human and mouse sequences and on the location in a region of conserved synteny we conclude that the *NDNL2* and *Ndn12* genes are orthologous in these two species.

The expression of *NDNL2* and *Ndn12* was analyzed by northern blot studies (Fig. 3). The observed 1.9 kb RNA transcript roughly corresponds in size to the 1.5 kb cDNA present in IMAGE clone 1134795, which likely contains most of the transcript. The transcript was observed in all human tissues tested, and appeared to be most abundant in testis after adjustments were made for RNA loading. Expression in mouse is also widespread, with a moderately abundant 1.7 kb transcript observed in all tissues tested consistent with the 1.5 kb insert size for cDNA clone RIKEN ID 1010001J10. The origin of the smaller transcript in mouse testis is unknown but may represent an alternative polyadenylation site or alternative transcriptional start site. It is notable that expression of *NDNL2/Ndn12* is widespread although for other family members, including *Ndn*, *Magel2* and *Dlxin*, the murine homologue of *MAGED1*, expression is more spatially and temporally limited [12,18,19].

Previous studies have suggested that the imprinted domain on chromosome 15q is limited to a region of about 1.5 Mb surrounding the imprinting center [20,21]. However, given the observed parent-of-origin effects in chro-

mosomal disorders of chromosome 15 [4], we performed experiments to analyze the imprinting of *NDNL2* and *Ndn12*. To test imprinting of *Ndn12*, we examined newborn brain, liver and lung, and embryonic day 12.5 whole embryo RNA samples from the offspring of an interspecific mouse cross for allelic expression using the same murine *MspI* polymorphism as used for genetic mapping. Both parental alleles were detected equally, indicating that expression of *Ndn12* is not imprinted (Fig. 4A). We were unable to identify an intragenic polymorphism in *NDNL2* that would allow direct evaluation of the levels of expression of each allele. Instead, we evaluated the effect of deletion of the chromosome 15q11-q13 imprinting center (IC) on the expression of *NDNL2*. Sporadic PWS and AS patients with *de novo* deletions not only have a loss of the genes located inside the deletion interval, they also have a loss of the imprinting control element located therein. In a previous study, a somatic, *de novo* deletion of the IC impaired imprinting of target genes [22]. These target genes are not necessarily limited to the region typically deleted in PWS and AS, which is defined by unstable genomic elements located at the deletion boundaries [1], but could include other genes within the range of the imprinting center. However, our previous study had predicted that it is unlikely that the range of the IC extended beyond the deletion itself [20]. To test this hypothesis and to examine the possibility that *NDNL2* is acted on by the IC, we tested the effect of the loss of the IC in sporadic PWS and AS patients on the expression of *NDNL2*. Using a previously defined assay [20], RNA from lymphoblast and fibroblast cell lines that carry either a paternal 15q11-q13 deletion (PWS) or the




**Figure 3**  
**Expression analysis necdin-like 2 in embryonic and adult human and mouse tissues.** (A) Northern blots of adult (left and center) and fetal (right) human tissues. The 1.9 kb *NDNL2* transcript is indicated by the arrow. Size markers are as indicated. (B) Northern blot of adult (left) and embryonic (right) mouse tissues shows expression of a 1.7 kb transcript (arrow).

equivalent maternal deletion (AS) were tested by RT-PCR for expression of *NDNL2*. On repeated trials, both cell lines expressed *NDNL2*, indicating that *NDNL2* is not imprinted by the imprinting center located in the deletion region (Fig. 4B).

The names *NDNL2/Ndnl2* have been approved by the human and mouse nomenclature committees, based on sequence similarity to *NDN* and chromosomal localization. In a recent review of the *NDN/MAGE* gene family, a multiple sequence alignment clustered the chromosome 15 family members (*NDN*, *MAGEL2/NDNL1*, and *NDNL2/MAGE-G*) together with the X-linked *MAGE-D*, *MAGE-E* and chromosome 3-linked *MAGE-F* genes [23]. *MAGE-D*, known more commonly as *NRAGE* (human) or *dlxin* (mouse) may be ancestral to other members of the *NDN/MAGE* gene family. We recommend

that the human and mouse nomenclature committees evaluate the arguments for the names of genes in this gene family to establish a unified nomenclature that clarifies the relationships among the family members.

Necdin was originally identified as a gene induced on neuronal differentiation of embryonic carcinoma cells, but has more recently been implicated in PWS. Members of the *MAGE* gene family are recognized for their expression in tumor cells, and a new family member *MAGED1* (*NRAGE/dlxin*) is postulated to have roles in chondrogenesis, neurotrophin signaling and apoptosis [19,24,25]. Although the widespread expression of *NDNL2* does not immediately suggest a role in the neurodevelopmental disorders associated with abnormalities of chromosome 15, *NDNL2* is located within the broad region associated with developmental disorders.

**Figure 4**

**Imprinting analysis of *NDNL2/Ndnl2*.** (A) Restriction digestion of PCR of genomic DNA from C57BL/6, SPRET and an F1 offspring demonstrating the interspecific polymorphism, RT-PCR of tissues (nb = newborn) from the F1 offspring. Note that both alleles are active. (B) RT-PCR of fibroblast (FB) and lymphoblast (LCL) RNA from PWS, AS and control samples. *NDNL2* is expressed in all cell lines whereas *SNRPN* is not expressed in PWS cell lines (i.e. is imprinted).

In particular, the location of *NDNL2* near D15S1019, proximal to D15S165 implies that copies of *NDNL2* are present on most phenotypically relevant inv dup(15) chromosomes [26,27] and may contribute to the findings in patients carrying these supernumerary chromosomes through a doubling of *NDNL2* expression levels. However, *NDNL2* is outside the more narrowed interstitial duplication interval associated with some autistic phenotypes [28], although long range effects on *NDNL2* expression may still occur.

### Conclusions

Given the wide range of processes that members of this intriguing gene family participate in and the possibility of redundant function within the gene family, we suggest that the 15q NDN/MAGE family members be considered as candidates for involvement in the neurodevelopmental disorders associated with chromosome 15q.

### Materials and methods

#### cDNA clones

Human and mouse cDNAs were obtained from Research Genetics or the MRC Genome Resource Facility and were sequenced using the Thermo Sequenase fluorescent labeled primer cycle sequencing kit with 7-deaza dGTP

(Amersham-Pharmacia Biotech, Buckinghamshire, England) and LiCor technology (LiCor 4200 Automatic Sequencer, Lincoln, Nebraska). The human cDNA was represented by IMAGE clone 1147395; mouse cDNAs were IMAGE clones 483464, 2101532 and RIKEN #1010001J10.

#### Northern blot expression studies

A PCR product derived from the 3' end of human *NDNL2* was generated with oligonucleotide primers NDNL2-3F (5'-GTCTACCCCAAGAAGCA) and NDNL2-4R (5'-CCTTCCCCCAATCCTCTAAA), in a 20 µl PCR reaction containing 20 pmol of each oligonucleotide. The PCR was performed as follows: 94°C for 5 min. followed by 30 cycles of 94°C for 30 s, 52°C for 30 s, 72°C for 30 s, and final extension at 72°C for 10 min., The PCR product was random prime <sup>32</sup>P-dCTP labeled with the Random Primers DNA Labeling System (Life Technologies, Rockville, MD). The labeled probe was hybridized to human adult and fetal Multiple Tissue Northern (MTN) Blots (Clontech Laboratories, Palo Alto, CA., Cat. #7760-1, 7759-1 and 7756-1) in ExpressHyb solution according to manufacturer's directions. The final wash was at 50°C in 0.1XSSC, 0.1%SDS twice for 20 min each time. Exposure to Hyperfilm (Amersham-Pharmacia Biotech) was for

four days at  $-80^{\circ}\text{C}$ . Oligonucleotide primers Ndn12-1F (5'-CTTGGAGTACCGGAGGATACC) and Ndn12-2R (5'-CAACACATCCTAACGCTCCA) were used for mouse northern blots. These primers amplified a 343 bp DNA fragment corresponding to the 3' end of the *Ndn12* gene. The PCR was performed as above but with an annealing temperature of  $58^{\circ}\text{C}$ . Mouse adult and embryo MTN blots (Cat. #7762-1 and 7763-1, Clontech Laboratories) were similarly hybridized with the radioactively labeled *Ndn12*1F/2R PCR product. To control for the amount of loaded RNA the same blot was subsequently hybridized with a  $\beta$ -actin or ubiquitin probe demonstrating approximately equal loading in all lanes.

### Genetic mapping and imprinting studies

A 469 bp product corresponding to the 3' end of *Ndn12* was generated from mouse genomic DNA (C57BL/J or SPRET/Ei) using oligonucleotide primers Ndn12-7F (5'-TGGAAACCAGCAAGATGAAA) and Ndn12-8R (5'-AGTACCCTGTTTCTTTATCGTC). DNA samples were sequenced on both strands using the LiCor automated sequencer. DNA amplification products were digested with *Msp*I to produce a 469 bp undigested product in C57BL/6J and 180 bp and 289 bp digested products in DNA from *M. spretus*. Genetic mapping was performed on the Jackson Laboratories BSS backcross. Cell lines used for human imprinting analysis were PWS lymphoblast GM09024B and AS lymphoblast GM11515 (both from the NIGMS Human Genetic Mutant Cell Repository), PWS fibroblast 1889 from the University of Miami Brain and Tissue Bank for Developmental Disorders and AS fibroblast KAT graciously provided by Dr. A. Beaudet (Baylor College of Medicine).

### List of abbreviations

AS (Angelman syndrome), ESTs, (expressed sequence tags), IC (imprinting center), PWS (Prader-Willi syndrome).

### Acknowledgements

We thank Mary Barter from the Jackson Laboratories for the murine haplotype analysis, the MRC Genome Resource Facility and the RIKEN Genome Science Center for DNA clones, and Dr. A. Beaudet for the AS fibroblast cell line. Samples used in this study were provided by the University of Miami Brain and Tissue Bank for Developmental Disorders through NICHD contract # NO1-HD-8-3284. This work was supported in part by a Research Grant No. 6-FY00-196 from the March of Dimes Birth Defects Foundation, Summer Studentships to T.K.C. from the Alberta Heritage Foundation for Medical Research (AHFMR) and the Canadian Genetic Disease Network. R.W. is a Scholar of the AHFMR and the Canadian Institutes of Health Research. Research involving human subjects and animals has been performed in accordance with the Institutional policies of the University of Alberta.

### References

- Amos-Landgraf JM, Ji Y, Gottlieb W, Depinet T, Wandstrat AE, Cassidy SB, Driscoll DJ, Rogan PK, Schwartz S, Nicholls RD: **Chromosome breakage in the Prader-Willi and Angelman syndromes involves recombination between large, transcribed repeats at proximal and distal breakpoints.** *Am. J. Hum. Genet* 1999, **65**:370-386
- Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH: **Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13).** *Hum. Mol. Genet* 1999, **8**:1025-1037
- Nicholls RD: **The impact of genomic imprinting for neurobehavioral and developmental disorders.** *J. Clin. Invest* 2000, **105**:413-418
- Maddox LO, Menold MM, Bass MP, Rogala AR, Pericak-Vance MA, Vance JM, Gilbert JR: **Autistic disorder and chromosome 15q11-q13: construction and analysis of a BAC/PAC contig.** *Genomics* 1999, **62**:325-331
- Bass MP, Menold MM, Wolpert CM, Donnelly SL, Ravan SA, Hauser ER, Maddox LO, Vance JM, Abramson RK, Wright HH, Gilbert JR, Cuccaro ML, DeLong GR, Pericak-Vance MA: **Genetic studies in autistic disorder and chromosome 15.** *Neurogenetics* 2000, **2**:219-226
- Matsuura T, Sutcliffe JS, Fang P, Galjaard R-J, Jiang Y-h, Benton CS, Rommens JM, Beaudet AL: **De novo truncation mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome.** *Nature Genet* 1997, **15**:74-77
- Kishino T, Lalonde M, Wagstaff J: **UBE3A/E6-AP mutations cause Angelman syndrome.** *Nature Genet* 1997, **15**:70-73
- MacDonald HR, Wevrick R: **The necdin gene is deleted in Prader-Willi syndrome and is imprinted in human and mouse.** *Hum. Mol. Genet* 1997, **6**:1873-1878
- Cavaille J, Buiting K, Kieffmann M, Lalonde M, Brannan CI, Horsthemke B, Bachellerie JP, Brosius J, Huttenhofer A: **From the cover: identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization.** *Proc. Natl. Acad. Sci. U S A* 2000, **97**:14311-14316
- de los Santos T, Schweizer J, Rees CA, Francke U: **Small evolutionarily conserved RNA, resembling C/D box small nucleolar RNA, is transcribed from PWCR1, a novel imprinted gene in the Prader-Willi deletion region, which is highly expressed in brain.** *Am. J. Hum. Genet* 2000, **67**:1067-1082
- Boccaccio I, Glatt-Deeley H, Watrin F, Roeckel N, Lalonde M, Muscatelli F: **The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region.** *Hum. Mol. Genet* 1999, **8**:2497-2505
- Lee S, Kozlov S, Hernandez L, Chamberlain SJ, Stewart CL, Wevrick R: **Expression and imprinting of MAGEL2 suggest a role in Prader-Willi syndrome and the homologous murine imprinting phenotype.** *Hum. Mol. Genet* 2000, **9**:1813-1819
- Jay P, Rougeulle C, Massacrier A, Moncla A, Mattei MG, Malzac P, Roeckel N, Taviaux S, Lefranc JL, Cau P, Berta P, Lalonde M, Muscatelli F: **The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region.** *Nature Genet* 1997, **17**:357-361
- Sutcliffe JS, Han M, Christian SL, Ledbetter DH: **Neuronally-expressed necdin gene: an imprinted candidate gene in Prader-Willi syndrome.** *Lancet* 1997, **350**:1520-1521
- Gerard M, Hernandez L, Wevrick R, Stewart C: **Disruption of the mouse necdin gene results in early postnatal lethality: a model for neonatal distress in Prader-Willi syndrome.** *Nature Genet* 1999, **23**:199-202
- Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Moal ML, Cau P, Cremer H: **Disruption of the mouse necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome.** *Hum. Mol. Genet* 2000, **9**:3101-3110
- Blanco G, Irving NG, Brown SD, Miller CC, McLoughlin DM: **Mapping of the human and murine X11-like genes (APBA2 and apba2), the murine Fe65 gene (Apbb1), and the human Fe65-like gene (APBB2): genes encoding phosphotyrosine-binding domain proteins that interact with the Alzheimer's disease amyloid precursor protein.** *Mamm. Genome* 1998, **9**:473-475
- Yoshikawa K: **Cell cycle regulators in neural stem cells and postmitotic neurons.** *Neurosci. Res* 2000, **37**:1-14
- Masuda Y, Sasaki A, Shibuya H, Ueno N, Ikeda K, Watanabe K: **Dlxin-1, a novel protein that binds Dlx5 and regulates its transcriptional function.** *J. Biol. Chem* 2000, **17**:5331-5338
- Lee S, Wevrick R: **Identification of novel imprinted transcripts in the Prader-Willi/Angelman syndrome deletion region: further evidence for regional imprinting control.** *Am. J. Hum. Genet* 2000, **66**:848-858

21. Meguro M, Mitsuya K, Nomura N, Kohda M, Kashiwagi A, Nishigaki R, Yoshioka H, Nakao M, Oishi M, Oshimura M: **Large-scale evaluation of imprinting status in the Prader-Willi syndrome region: an imprinted direct repeat cluster resembling small nucleolar RNA genes.** *Hum. Mol. Genet* 2001, **10**:383-394
22. Bielinska B, Blaydes SM, Buiting K, Yang T, Krajewska-Walasek M, Horsthemke B, Brannan CI: **De novo deletions of SNRPN exon I in early human and mouse embryos result in a paternal to maternal imprint switch.** *Nat Genet* 2000, **25**:74-78
23. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S: **An overview of the MAGE gene family with the identification of all human members of the family.** *Cancer Res* 2001, **61**:5544-5551
24. Jordan BW, Dinev D, LeMellay V, Troppmair J, Gotz R, Wixler L, Sendtner M, Ludwig S, Rapp UR: **NRAGE is an inducible IAP-interacting protein that augments cell death.** *J. Biol. Chem* 2001, **6**:1-6
25. Salehi AH, Roux PP, Kubu CJ, Zeindler C, Bhakar A, Tannis LL, Verdi JM, Barker PA: **NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis.** *Neuron* 2000, **27**:279-288
26. Wandstrat AE, Leana-Cox J, Jenkins L, Schwartz S: **Molecular cytogenetic evidence for a common breakpoint in the largest inverted duplications of chromosome 15.** *Am J Hum Genet* 1998, **62**:925-936
27. Wandstrat AE, Schwartz S: **Isolation and molecular analysis of inv dup(15) and construction of a physical map of a common breakpoint in order to elucidate their mechanism of formation.** *Chromosoma* 2000, **109**:498-505
28. Repetto GM, White LM, Bader PJ, Johnson D, Knoll JH: **Interstitial duplications of chromosome region 15q11q13: clinical and molecular characterization.** *Am. J. Med. Genet* 1998, **79**:82-89

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)